Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3σ case.

Targeting the binding site of 14-3-3 proteins lets the release of partner proteins involved in cell cycle progression, apoptosis, cytoskeletal rearrangement and transcriptional regulation and may therefore be regarded as an alternative strategy to integrate conventional therapeutic approaches against cancer. In the present work, we report the identification of two new small molecule inhibitors of 14-3-3σ/c-Abl protein-protein interaction (BV01 and BV101) discovered by means of computational methods. The most interesting compound (BV01) showed a lethal dose (LD(50)) in the low micromolar range against Ba/F3 murine cell lines expressing the Imatinib (IM)-sensitive wild type Bcr-Abl construct and the IM-resistant Bcr-Abl mutation T315I. BV01 interaction with 14-3-3σ was demonstrated by NMR studies and elucidated by docking. It blocked the binding domain of 14-3-3σ, hence promoting the release of the partner protein c-Abl (the one not involved in Bcr rearrangement), and its translocation to both the nuclear compartment and mitochondrial membranes to induce a pro-apoptotic response. Our results advance BV01 as a confirmed hit compound capable of eliciting apoptotic death of Bcr-Abl-expressing cells by interfering with 14-3-3σ/c-Abl protein-protein interaction.

[1]  M. Yaffe,et al.  A Structural Basis for 14-3-3σ Functional Specificity*♦ , 2005, Journal of Biological Chemistry.

[2]  F. Baldanti,et al.  Toward the Discovery of Novel Anti‐HIV Drugs. Second‐Generation Inhibitors of the Cellular ATPase DDX3 with Improved Anti‐HIV Activity: Synthesis, Structure–Activity Relationship Analysis, Cytotoxicity Studies, and Target Validation , 2011, ChemMedChem.

[3]  H. Hermeking.  The 14-3-3 cancer connection , 2003, Nature Reviews Cancer.

[4]  S. Yao,et al.  Microarray-assisted high-throughput identification of a cell-permeable small-molecule binder of 14-3-3 proteins. , 2010, Angewandte Chemie.

[5]  D. E. Clark,et al.  Flexible docking using tabu search and an empirical estimate of binding affinity , 1998, Proteins.

[6]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[7]  Fabrizio Manetti,et al.  Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. , 2010, Bioorganic & medicinal chemistry letters.

[8]  H. Hermeking,et al.  14-3-3 proteins in cell cycle regulation. , 2006, Seminars in cancer biology.

[9]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[10]  G. Tzivion,et al.  14-3-3 proteins as potential oncogenes. , 2006, Seminars in cancer biology.

[11]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[12]  M. Botta,et al.  A New Nonpeptidic Inhibitor of 14-3-3 Induces Apoptotic Cell Death in Chronic Myeloid Leukemia Sensitive or Resistant to Imatinib , 2011, Journal of Pharmacology and Experimental Therapeutics.

[13]  M. Radi,et al.  C6‐Unsubstituted Pyrazolo[3,4‐d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines , 2009, ChemMedChem.

[14]  J. Matthews,et al.  Protein-protein interactions in human disease. , 2005, Current opinion in structural biology.

[15]  G. Martinelli,et al.  14‐3‐3 Ligand Prevents Nuclear Import of c‐ABL Protein in Chronic Myeloid Leukemia , 2009, Traffic.

[16]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[17]  E Ruoslahti,et al.  Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. , 1999, Biochemistry.